Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 26-27, 2016

Alexandria, VA

Scientific Agenda

Friday, August 26, 2016

9:30 am

Welcome and introduction
Srdan Verstovsek, MD, PhD

Session I: Biology of Myeloproliferative Neoplasms and Myelodysplastic Syndromes

Moderator: Jerry Spivak, MD

9:40 am

Pre-session audience survey

9:45 am

Genetic basis of MDS
Timothy Graubert, MD

10:05 am

Inflammation in MDS
Dan T. Starczynowski, PhD

10:25 am

New mouse models of MDS
Simona Colla, PhD

10:45 am

Break

11:15 am

Cytokines, cells and inflammation in MPN
Jerry Spivak, MD

11:35 am

Interplay of somatic and germline variants in MPN
Stephen T. Oh, MD, PhD

11:55 am

Panel discussion and post-session audience survey

12:15 pm

Moderator take-home points

12:20 pm

Lunch

Session II: Clinical Aspects of Myeloproliferative Neoplasms (I)

Moderator: Richard T. Silver, MD

2:20 pm

Pre-session audience survey

2:25 pm

Biology and Therapy of Eosinophilic MPNs
Jason R. Gotlib, MD, MS

2:45 pm

The WHO updated diagnostic criteria for ET, PV & MF
Mark Heaney, MD, PhD

3:05 pm

Splanchnic vein thrombosis and MPN: Diagnosis and therapy
Michael Kroll, MD

3:25 pm

Break

3:55 pm

Update on long-acting interferons for MPN
Richard T. Silver, MD

4:15 pm

JAK inhibitors for ET and PV: What have we learned so far
Ellen Ritchie, MD

4:35 pm

Panel discussion and post-session audience survey

4:55 pm

Moderator take-home points

5:00 pm

Adjourn

 

Saturday, August 27, 2016

9:30 am

Welcome to Day 2
Srdan Verstovsek, MD, PhD

Session III: Clinical Aspects of Myelodysplastic Syndromes

Moderator: Guillermo Garcia-Manero, MD

9:40 am

Pre-session audience survey

9:45 am

An approach to diagnosis and staging of MDS: From morphology to genetics
Amy E. DeZern, MD, MHS

10:05 am

A unified approach to lower risk MDS: Standard and emerging therapies
Guillermo Garcia-Manero, MD

10:25 am

A unified approach to higher risk MDS: Standard and emerging therapies
Bart Scott, MD

10:45 am

Break

11:15 am

How to approach HMA failure?
Guillermo Garcia-Manero, MD

11:35 am

Stem cell transplant approaches to MDS
Michael R. Grunwald, MD

11:55 am

Panel discussion and post-session audience survey

12:15 pm

Moderator take-home points

12:20 pm

Lunch

Session IV: Clinical Aspects of Myeloproliferative Neoplasms (II)

Moderator: Elliot Winton, MD

2:20 pm

Pre-session audience survey

2:25 pm

Therapy for “early MF”: pros and cons
Ruben A. Mesa, MD

2:45 pm

Mutation-based risk stratification approaches in MF: Any real clinical utility?
Elliot Winton, MD

3:05 pm

Update on JAK inhibitors for myelofibrosis: There is more than one
Rami Komrokji, MD

3:25 pm

Break

3:55 pm

Influence of mutational status on timing, outcome and post-transplant management of MF patients
Uday R. Popat, MD

4:15 pm

Novel agents and combination therapies in MF
Srdan Verstovsek, MD, PhD

4:35 pm

Panel discussion and post-session audience survey

4:55 pm

Moderator take-home points

5:00 pm

Adjourn